Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory
Read Article
Two recent reports further characterize the newly described, Kawasaki-like, syndrome affecting children with COVID-19 infections.
The NEJM describes the childhood syndrome as having Kawasaki’s disease, fever, toxic shock syndrome, acute abdominal conditions, and encephalopathy; hence the label
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection has both similarities and differences with Kawasaki disease, and requires distinct clinical management, according to draft guidance from the American College of Rheumatology (ACR).
Age, symptoms,
Read Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still's disease (AOSD), the first ever FDA approved drug for AOSD.
Canakinumab, an interleukin-1 inhibitor, was FDA approved in 2013 for use children (aged 2 years and older) with systemic juvenile idiopathic
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The
Read Article
Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients. Yet, a recent report reaffirms what rheumatologists have known for years - that HCQ use is associated with better outcomes in systemic lupus erythematosus, including
Read Article
Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.
Read Article
BCG & COVID: 1) Israeli study shows BCG vaccination during childhood had no protective effect on getting COVID-19 infection later. 2) Bladder cancer pts on BCG therapy who get COVID infection, can safely take IL-6 or IL-1 inhibitors, Just not TNF inhib.
Dr. John Cush RheumNow ( View Tweet)
As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.
In New York, up to 102 children have reportedly developed this inflammatory syndrome, and three
Read Article
The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.
These preliminary recommendations are based on an expert consensus from 17
Pediatricians are asking the question - could this be a rare manifestation of COVID-19 in children?
There are now 3 case reports in the U.S of children infected with the coronavirus who have developed what looks like Kawasaki's diseaes. Simimar reports have been seen in the UK, Italy
Read Article
Early reports on the COVID-19 pandemic allude to a cytokine storm or hyper-inflammation, especially in patients who succumbed to the illness. These conclusions are based on elevated levels of ferritin and other inflammatory markers, drawing comparisons to rare diseases of uncontrolled
Read Article
Dr. Jack Cush reviews the appproach to evaluating fever in adults suspected of having a rheumatic disease, Stills disease or autoinflammatory conditions. Presentations, fever duration, disease criteria and genetic testing are discussed.
Read Article
Dr. Jack Cush reviews the news, journal articles and new ACR COVID-19 guidelines from the past week on RheumNow.com.
With the COVID-19 pandemic dynamically changing, we have provided several news items germane to the Rheumatologist.
Read Article
An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK).
A total of 141 AOSD patients were retrospectively studied.
Overall, they found no differences in efficacy if ANK was started
Read Article
